A preliminary clinical trial to evaluate 64Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancer

被引：0
|
作者：
Inki Lee
Ilhan Lim
Byung Hyun Byun
Byung Il Kim
Chang Woon Choi
Sang-Keun Woo
Kwang Il Kim
Kyo Chul Lee
Joo Hyun Kang
Min-Ki Seong
Hyun-Ah Kim
Woo Chul Noh
Sang Moo Lim
机构：
[1] Korea Institute of Radiological and Medical Sciences,Department of Nuclear Medicine, Korea Cancer Centre Hospital
[2] Korea Institutes of Radiological and Medical Sciences,Division of Applied RI, Research Institute of Radiological and Medical Sciences
[3] Korea Institutes of Radiological and Medical Sciences,Department of Surgery, Korea Cancer Centre Hospital
来源：
EJNMMI Research | / 11卷
关键词：
HER-2; Cu-NOTA-Trastuzumab; Breast cancer; Positron emission tomography; Computed tomography;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Positron emission tomography using [F-18]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: Preliminary study
    Inoue, T
    Kim, EE
    Wallace, S
    Yang, DJ
    Wong, FCL
    Bassa, P
    Cherif, A
    Delpassand, E
    Buzdar, A
    Podoloff, DA
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1996, 11 (04) : 235 - 245
  • [22] Pravastatin stimulates angiogenesis in a murine hindlimb ischemia model: a positron emission tomography imaging study with 64Cu-NOTA-TRC105
    Orbay, Hakan
    Hong, Hao
    Koch, Jill M.
    Valdovinos, Hector F.
    Hacker, Timothy A.
    Theuer, Charles P.
    Barnhart, Todd E.
    Cai, Weibo
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2014, 6 (01): : 54 - 63
  • [23] Positron emission tomography imaging in breast cancer: a pictorial essay
    Lim, C. Y.
    Tan, E. H.
    Tan, J. W.
    EJC SUPPLEMENTS, 2010, 8 (03): : 239 - 239
  • [24] Evolving role of positron emission tomography in breast cancer imaging
    Eubank, WB
    Mankoff, DA
    SEMINARS IN NUCLEAR MEDICINE, 2005, 35 (02) : 84 - 99
  • [25] Imaging mouse models of breast cancer with positron emission tomography
    S Cherry
    C Abbey
    S Borowsky
    J Gregg
    R Cardiff
    Breast Cancer Research, 5 (Suppl 1)
  • [26] Correlation of 64Cu-DOTA-trastuzumab positron emission tomography (PET) imaging with HER2 status by immunohistochemistry (IHC).
    Mortimer, Joanne E.
    Park, Jinha Mark
    Carroll, Mary I.
    Poku, Kofi
    Miles, Joshua
    Colcher, David
    Raubitschek, Andrew Antony
    Tri Tran
    Bading, James R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] VPAC1 Targeted 64Cu-TP3805 Positron Emission Tomography Imaging of Prostate Cancer: Preliminary Evaluation in Man
    Tripathi, Sushil
    Trabulsi, Edouard J.
    Gomella, Leonard
    Kim, Sung
    McCue, Peter
    Intenzo, Charles
    Birbe, Ruth
    Gandhe, Ashish
    Kumar, Pardeep
    Thakur, Mathew
    UROLOGY, 2016, 88 : 111 - 118
  • [28] Relationship between 64Cu-DOTA-trastuzumab positron emission tomography uptake and assessment of HER2 by immunohistochemistry in women with advanced breast cancer
    Mortimer, J. E.
    Colcher, D.
    Frankel, P.
    Raubitschek, A.
    Carroll, M.
    Conti, P.
    Tong, S.
    Poku, K.
    Miles, J.
    Bading, J.
    CANCER RESEARCH, 2013, 73
  • [29] Zirconium-89-Trastuzumab Positron Emission Tomography As a Tool to Solve a Clinical Dilemma in a Patient With Breast Cancer
    Gaykema, Sietske B. M.
    Brouwers, Adrienne H.
    Hovenga, Sjoerd
    Lub-de Hooge, Marjolijn N.
    de Vries, Elizabeth G. E.
    Schroder, Caroline P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (06) : E74 - E75
  • [30] Positron Emission Tomography (PET) and breast cancer in clinical practice
    Lavayssiere, Robert
    Cabee, Anne-Elizabeth
    Filmont, Jean-Emmanuel
    EUROPEAN JOURNAL OF RADIOLOGY, 2009, 69 (01) : 50 - 58
12345